Claims for Patent: 9,284,369

Summary for Patent: 9,284,369

Title:	Inhibition of angiogenesis
Abstract:	The present invention relates generally to the inhibition of inflammatory cell-mediated angiogenesis. In particular, the invention concerns the prevention or treatment of tumor angiogenesis, and the inhibition of tumor development, using Bv8 antagonists, such as anti-Bv8 antibodies.
Inventor(s):	Ferrara; Napoleon (San Francisco, CA), Shojaei; Farbod (San Diego, CA), Wu; Xiumin (San Bruno, CA), Zhong; Cuiling (Palo Alto, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	12/679,257
Patent Claims:	1. A method of tumor treatment in a human subject having a tumor refractory to treatment with a vascular endothelial growth factor (VEGF) antagonist, comprising administering to said human subject an effective amount of an anti-Bv8 antibody or an antigen-binding fragment thereof and an effective amount of an anti-VEGF antibody or an antigen-binding fragment thereof. 2. The method of claim 1 wherein the anti-VEGF antibody is bevacizumab. 3. The method of claim 1 wherein the anti-Bv8 antibody or the antigen-binding fragment thereof is chimeric, humanized or human. 4. The method of claim 1 further comprising subjecting said human subject to chemotherapy or radiation therapy. 5. The method of claim 1, wherein the human subject has a tumor refractory to monotherapy with a VEGF antagonist.

Details for Patent 9,284,369

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-02-26